Brain Cancer Cells Attract Stem Cells for Angiogenesis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 10
Volume 15
Issue 10

New research shows that in order to grow, gliomas attract stem cells circulating in the blood to develop new blood vessels, as well as using blood vessels from the brain itself.

COLUMBUS, Ohio—New research shows that in order to grow, gliomas attract stem cells circulating in the blood to develop new blood vessels, as well as using blood vessels from the brain itself. The animal study found that in gliomas, about 75% of new blood vessels in the tumor come from the surrounding brain, but that about 25% come from progenitor cells. The research also showed that the progenitor cells are drawn to the tumor because the tumor cells secrete stromal-derived factor-1 (SDF-1), a factor that regulates vasculogenesis.

"These findings indicate that blocking blood vessel growth in tumors will probably require multiple drugs, some that inhibit the growth of blood vessels coming from the surrounding brain and co-opted into the tumor, and some that inhibit blood vessels that form from endothelial progenitor cells," said principal investigator, E. Antonio Chiocca, MD, PhD, professor of neurological surgery and co-director of Ohio State University's Dardinger Center for Neuro-oncology. The research, published online September 15 in the journal Cancer Research, was largely performed while Dr. Chiocca was at Massachusetts General Hospital and Harvard Medical School, in collaboration with Drs. David Scadden, Manish Aghi, and Kenneth Cohen.

The researchers transferred fluorescent tagged bone marrow cells from one set of mice into another in which the bone marrow was destroyed. Mouse glioma cells were then implanted into the animals' brains and under the skin. As the tumors grew, blood vessels that developed from the progenitor cells fluoresced, while those that developed from the brain did not. Further research showed that "if the tumor doesn't make SDF-1, the progenitor cells won't travel to it," Dr. Chiocca commented.

Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.